Tags |
|
|
Links |
|
|
Advice You - To Personalize Or Not To...That is the Question
If you are really interested in conducting a successful, effectiv
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
e email campaign, you need to personalize your messages.
One sol
One sol
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
tion is Mail It Safe, a new email messaging solution that sends c
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
onfidential, critical email with automatic personalization (the r
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
cipients first name). Secondarily, Mail It Safe also tracks your
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
mails, with real-time reporting of when your email was opened, ho
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
w long it was read, as well as any attachments.
You can only use
You can only use
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
it for a maximum of 50 email addresses, a spam precaution.
The o
The o
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
her solution to automatic personalization is to use an autorespon
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
der. A good one is: isoresponder.com, you can review
at: http:/
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
www.ad-alyzer.com/727/737813459265
But don't overdo it…as with a
But don't overdo it…as with a
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
ything, you can overdo a good thing and it will bite you in the b
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
utt :o)
If you have opt in subscribers, many times they either d
If you have opt in subscribers, many times they either d
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
n't give you their first name in the signup form or email link, o
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
a fictitious one. So instead of your email message looking like:
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
Hi Bob,
It might look like, "Hi Reader" or "Hi Prospect"
Anot
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
er point is to not put the first name in subject line. It looks t
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
o phony and hypy. Especially if you say, "Hi Bob" in the subject
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
line, they will think its from family or friends and will be angr
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
when they find out its not.
Use personalization, but be careful
Use personalization, but be careful
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.adviceyou.org.ua/article/62900/adviceyou-To-Personalize-Or-Not-ToThat-is-the-Question.html">To Personalize Or Not To...That is the Question</a>
BB link (for phorums):
[url=http://www.adviceyou.org.ua/article/62900/adviceyou-To-Personalize-Or-Not-ToThat-is-the-Question.html]To Personalize Or Not To...That is the Question[/url]
Related Articles:
Leading Change - Big Titles Don't Mean Big Honesty
What Every Pet-Care Business Owner Should Have in their PR Tool Chest
10 Analyzing Tips for Your eBay Transactions
Bookmark it:
|